Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials
This pooled analysis of two phase 3 trials demonstrates that DAXI is an effective, safe, and long-acting treatment for CD. Key adverse events occurred at rates lower than prior pivotal trials of BoNTs for CD.
Authors
- Aaron Ellenbogen (ORCID: https://orcid.org/0000-0002-4086-8336)
- Todd M. Gross (ORCID: https://orcid.org/0000-0001-5482-5313)
- Conor J. Gallagher (ORCID: https://orcid.org/0000-0002-5488-6594)
- Lingjing Jin (ORCID: https://orcid.org/0000-0001-7199-2578)
- Atul T. Patel (ORCID: https://orcid.org/0000-0003-2765-7953)
- David Hollander
- Rashid Kazerooni (ORCID: https://orcid.org/0000-0003-3223-2597)
- Xingyue Hu (ORCID: https://orcid.org/0000-0001-6865-6098)
- Guanghua Lei (ORCID: https://orcid.org/0000-0003-2987-138X)
- Hui Wang (ORCID: https://orcid.org/0000-0002-7970-6772)
- Fan Xiaojing
- Wan Xinhua
- Marta Banach
Institutions
- Jagiellonian University (PL)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Fosun Pharma (China) (CN)
- ESI Group (United States) (US)
- Shanghai Sunshine Rehabilitation Center (CN)
- Michigan Ear Institute (US)
- Covance (United States) (US)
- Zhejiang University (CN)
Publication Details
- Journal
- Parkinsonism & Related Disorders
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1016/j.parkreldis.2025.108015
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Revance